Abstract
In most patients with progressive systemic sclerosis (PSS) the oesophagus is affected. Reflux symptoms are most frequent, whilst dysphagia also occurs. Cisapride, a prokinetic agent, may enhance motility along the gastrointestinal tract. The effects of cisapride on oesophageal transit were evaluated in 12 PSS patient using a solid-phase radionuclide oesophageal transit study. Each PSS patient was given cisapride 10 mg or placebo orally three times a day in a random, double-blind, crossover fashion. The results show that cisapride does not seem to have any impact on oesophageal transit in patients with PSS.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Cisapride / administration & dosage
-
Cisapride / therapeutic use*
-
Cross-Over Studies
-
Double-Blind Method
-
Esophageal Motility Disorders / diagnostic imaging
-
Esophageal Motility Disorders / drug therapy*
-
Esophageal Motility Disorders / etiology*
-
Esophageal Motility Disorders / physiopathology
-
Esophagus / diagnostic imaging
-
Esophagus / drug effects*
-
Esophagus / physiopathology*
-
Female
-
Gastrointestinal Agents / adverse effects
-
Gastrointestinal Agents / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Radionuclide Imaging
-
Scleroderma, Systemic / complications*
-
Treatment Outcome
Substances
-
Gastrointestinal Agents
-
Cisapride